The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
Ogura, Y., Bonen, D. K., Inohara, N., Nicolae, D. L., Chen, F. F., Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr, R. H., et al. (2001) · Nature · doi:10.1038/35079114 · Cited by 5,030
Podolsky, D. K. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020831 · Cited by 3,159
Genetics and pathogenesis of inflammatory bowel disease
Khor, B., Gardet, A., & Xavier, R. J. (2011) · Nature · doi:10.1038/nature10209 · Cited by 2,614
Inflammatory bowel disease: Etiology and pathogenesis
Fiocchi, C. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70381-6 · Cited by 2,059
Treatment of Murine Colitis by Lactococcus lactis Secreting Interleukin-10
Steidler, L., Hans, W., Schotte, L., Neirynck, S., Obermeier, F., Falk, W., Fiers, W., & Remaut, E. (2000) · Science · doi:10.1126/science.289.5483.1352 · Cited by 1,513
Kararli, T. T. (1995) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2510160502 · Cited by 1,459
Nod2, a Nod1/Apaf-1 Family Member That Is Restricted to Monocytes and Activates NF-κB
Ogura, Y., Inohara, N., Benito, A., Chen, F. F., Yamaoka, S., & Núñez, G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008072200 · Cited by 1,361
The Immunology of Mucosal Models of Inflammation
Strober, W., Fuss, I. J., & Blumberg, R. S. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064816 · Cited by 1,304
Zeissig, S., Bürgel, N., Günzel, D., Richter, J., Mankertz, J., Wahnschaffe, U., Kroesen, A. J., Zeitz, M., Fromm, M., & Schulzke, J.-D. (2007) · Gut · doi:10.1136/gut.2006.094375 · Cited by 1,223
Transit of pharmaceutical dosage forms through the small intestine.
Davis, S. S., Hardy, J. G., & Fara, J. W. (1986) · Gut · doi:10.1136/gut.27.8.886 · Cited by 853
Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug Delivery
Das, S., & Chaudhury, A. (2011) · AAPS PharmSciTech · doi:10.1208/s12249-010-9563-0 · Cited by 838
Muller, R. H., & Keck, C. M. (2004) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2004.06.007 · Cited by 819
AN EXPERIMENT TO DETERMINE THE ACTIVE THERAPEUTIC MOIETY OF SULPHASALAZINE
Khan, A. K. A., Piris, J., & Truelove, S. C. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90831-5 · Cited by 814
Wilson, D. S., Dalmasso, G., Wang, L., Sitaraman, S. V., Merlin, D., & Murthy, N. (2010) · Nature Materials · doi:10.1038/nmat2859 · Cited by 747
Protein Instability in Poly(Lactic-co-Glycolic Acid) Microparticles
van de Weert, M., Hennink, W. E., & Jiskoot, W. (2000) · Pharmaceutical Research · doi:10.1023/a:1026498209874 · Cited by 708
NUGENT, S. G., KUMAR, D., RAMPTON, D. S., & EVANS, D. F. (2001) · Gut · doi:10.1136/gut.48.4.571 · Cited by 700
Frequency of glucocorticoid resistance and dependency in Crohn's disease.
Munkholm, P., Langholz, E., Davidsen, M., & Binder, V (1994) · Gut · doi:10.1136/gut.35.3.360 · Cited by 654
Intestinal barrier dysfunction in inflammatory bowel diseases
McGuckin, M. A., Eri, R., Simms, L. A., Florin, T. H. J., & Radford-Smith, G. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20539 · Cited by 627
Stabilization of proteins encapsulated in injectable poly (lactide- co-glycolide)
Zhu, G., Mallery, S. R., & Schwendeman, S. P. (2000) · Nature Biotechnology · doi:10.1038/71916 · Cited by 609
IL-1β Causes an Increase in Intestinal Epithelial Tight Junction Permeability
Al-Sadi, R. M., & Ma, T. Y. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4641 · Cited by 601
Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation
Aouadi, M., Tesz, G. J., Nicoloro, S. M., Wang, M., Chouinard, M., Soto, E., Ostroff, G. R., & Czech, M. P. (2009) · Nature · doi:10.1038/nature07774 · Cited by 573
Steidler, L., Neirynck, S., Huyghebaert, N., Snoeck, V., Vermeire, A., Goddeeris, B., Cox, E., Remon, J. P., & Remaut, E. (2003) · Nature Biotechnology · doi:10.1038/nbt840 · Cited by 542
Size-Dependent Bioadhesion of Micro- and Nanoparticulate Carriers to the Inflamed Colonic Mucosa
Lamprecht, A., Schäfer, U., & Lehr, C.-M. (2001) · Pharmaceutical Research · doi:10.1023/a:1011032328064 · Cited by 507
Self-citationMouse models of inflammatory bowel disease☆
WIRTZ, S., & NEURATH, M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.07.003 · Cited by 507
Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target
Peer, D., Park, E. J., Morishita, Y., Carman, C. V., & Shimaoka, M. (2008) · Science · doi:10.1126/science.1149859 · Cited by 493
A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis
Ogata, H., Matsui, T., Nakamura, M., Iida, M., Takazoe, M., Suzuki, Y., & Hibi, T. (2006) · Gut · doi:10.1136/gut.2005.081794 · Cited by 462
Ma, T. Y., Boivin, M. A., Ye, D., Pedram, A., & Said, H. M. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00412.2004 · Cited by 452
Recent trends in the epidemiology of inflammatory bowel diseases: Up or down
Lakatos, P. L. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i38.6102 · Cited by 446
Gut instincts: Explorations in intestinal physiology and drug delivery
McConnell, E. L., Fadda, H. M., & Basit, A. W. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.05.012 · Cited by 431
Lichtenstein, G. R., Abreu, M. T., Cohen, R., & Tremaine, W. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.048 · Cited by 417
Biodegradable Nanoparticles for Targeted Drug Delivery in Treatment of Inflammatory Bowel Disease
Lamprecht, A., Ubrich, N., Yamamoto, H., Schäfer, U., Takeuchi, H., Maincent, P., Kawashima, Y., & Lehr, C.-M. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29290-9 · Cited by 403
Self-citationLipid Nanoparticles with a Solid Matrix (SLN®, NLC®, LDC®) for Oral Drug Delivery
Muchow, M., Maincent, P., & Müller, R. H. (2008) · Drug Development and Industrial Pharmacy · doi:10.1080/03639040802130061 · Cited by 394
Lichtenstein, G. R., Sbreu, M. T., Cohen, R. D., & Tremaine, W. J. (2006) · PubMed · Cited by 371
Polysaccharides for Colon Targeted Drug Delivery
Chourasia, M. K., & Jain, S. K. (2004) · Drug Delivery · doi:10.1080/10717540490280778 · Cited by 349
Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Ford, A. C., Bernstein, C. N., Khan, K. J., Abreu, M. T., Marshall, J. K., Talley, N. J., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.70 · Cited by 328
Batrakova, E. V., Gendelman, H. E., & Kabanov, A. V. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.559457 · Cited by 323
KOJOUHAROFF, G., HANS, W., OBERMEIER, F., MA¨NNEL, D. N., ANDUS, T., SCHO¨LMERICH, J., GROSS, V, & FALK, W. (2003) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1997.291-ce1184.x · Cited by 317
Bilati, U., Allémann, E., & Doelker, E. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.10.006 · Cited by 313
Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN®) versus drug nanocrystals
Müller, R. H., Runge, S., Ravelli, V., Mehnert, W., Thünemann, A. F., & Souto, E. B. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.02.045 · Cited by 304
Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis
Vandenbroucke, K., de Haard, H., Beirnaert, E., Dreier, T., Lauwereys, M., Huyck, L., Van Huysse, J., Demetter, P., Steidler, L., Remaut, E., et al. (2010) · Mucosal Immunology · doi:10.1038/mi.2009.116 · Cited by 289
Intestinal permeability, leaky gut, and intestinal disorders
Hollander, D. (1999) · Current Gastroenterology Reports · doi:10.1007/s11894-999-0023-5 · Cited by 258
Laroui, H., Dalmasso, G., Nguyen, H. T. T., Yan, Y., Sitaraman, S. V., & Merlin, D. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.003 · Cited by 253
Jiskoot, W., Randolph, T. W., Volkin, D. B., Russell Middaugh, C., Schöneich, C., Winter, G., Friess, W., Crommelin, D. J. A., & Carpenter, J. F. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23018 · Cited by 251
Gastrointestinal pH profiles in patients with inflammatory bowel disease
Press, Hauptmann, Hauptmann, Fuchs, Fuchs, Ewe, & Ramadori (1998) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1998.00358.x · Cited by 246
Very low intraluminal colonic pH in patients with active ulcerative colitis
Fallingborg, J., Christensen, L. A., Jacobsen, B. A., & Rasmussen, S. N. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01297074 · Cited by 226
Leonard, F., Collnot, E.-M., & Lehr, C.-M. (2010) · Molecular Pharmaceutics · doi:10.1021/mp1000795 · Cited by 223
Self-citationHead, K. A., & Jurenka, J. S. (2003) · PubMed · Cited by 221
MULLER, R. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.07.006 · Cited by 199
Makhlof, A., Tozuka, Y., & Takeuchi, H. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.12.013 · Cited by 192
New pathophysiological insights and modern treatment of IBD
Engel, M. A., & Neurath, M. F. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0219-3 · Cited by 189
Lamprecht, A., Yamamoto, H., Takeuchi, H., & Kawashima, Y. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.088146 · Cited by 187
Defensins and inflammation: The role of defensins in inflammatory bowel disease
Ramasundara, M., Leach, S. T., Lemberg, D. A., & Day, A. S. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05772.x · Cited by 182
TABATA, Y. (1996) · Vaccine · doi:10.1016/s0264-410x(96)00149-1 · Cited by 181
Pharmacokinetics of Budesonide (Entocort??? EC) Capsules for Crohn???s Disease
Edsb??cker, S., & Andersson, T. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443120-00003 · Cited by 181
Kriegel, C., & Amiji, M. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.002 · Cited by 176
Drug delivery to the proximal colon
Hardy, J. G., Wilson, C. G., & Wood, E. (1985) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1985.tb04992.x · Cited by 169
SIMONOSKACRCAREVSKA, M. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.06.007 · Cited by 166
Colon-specific delivery of 5-aminosalicylic acid from chitosan-Ca-alginate microparticles
Mladenovska, K., Raicki, R. S., Janevik, E. I., Ristoski, T., Pavlova, M. J., Kavrakovski, Z., Dodov, M. G., & Goracinova, K. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.05.028 · Cited by 166
Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes
Jubeh, T. T., Barenholz, Y., & Rubinstein, A. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000019298.29561.cd · Cited by 164
Laroui, H., Theiss, A. L., Yan, Y., Dalmasso, G., Nguyen, H. T. T., Sitaraman, S. V., & Merlin, D. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.09.062 · Cited by 157
Colonic Drug Delivery: Prodrug Approach
Sinha, V. R., & Kumria, R. (2001) · Pharmaceutical Research · doi:10.1023/a:1011033121528 · Cited by 149
Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease
Klotz, U. E., & Schwab, M. G. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.08.007 · Cited by 147
Gastrointestinal Motility Disorders in Patients with Inactive Crohn's Disease
Annese, V., Bassotti, G., Napolitano, G., Usai, P., Andriulli, A., & Vantrappen, G. R. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709002989 · Cited by 139
Peterson, C. G., Eklund, E., Taha, Y., Raab, Y., & Carlson, M. (2002) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05837.x · Cited by 137
Effects of Nanocrystalline Silver (NPI 32101) in a Rat Model of Ulcerative Colitis
Bhol, K. C., & Schechter, P. J. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9738-4 · Cited by 135
Dretzke, J., Edlin, R. P., Round, J. A., Connock, M. J., Hulme, C. T., Czeczot, J., Fry-Smith, A., McCabe, C. J., & Meads, C. (2011) · Health Technology Assessment · doi:10.3310/hta15060 · Cited by 134
Selective nanoparticle adhesion can enhance colitis therapy
Lamprecht, A. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.66 · Cited by 131
Bhavsar, M. D., & Amiji, M. M. (2008) · Gene Therapy · doi:10.1038/gt.2008.67 · Cited by 131
5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease
Pertuit, D., Moulari, B., Betz, T., Nadaradjane, A., Neumann, D., Ismaïli, L., Refouvelet, B., Pellequer, Y., & Lamprecht, A. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.08.008 · Cited by 129
Nanoparticles in inflammatory bowel disease: Particle targeting versus pH-sensitive delivery
Meißner, Y., Pellequer, Y., & Lamprecht, A. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.01.032 · Cited by 120
A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles
Lamprecht, A., Yamamoto, H., Takeuchi, H., & Kawashimà, Y. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.02.011 · Cited by 118
Targeted delivery of therapeutics to endothelium
Simone, E. A., Ding, B., & Muzykantov, V. R. (2008) · Cell and Tissue Research · doi:10.1007/s00441-008-0676-7 · Cited by 116
Tahara, K., Samura, S., Tsuji, K., Yamamoto, H., Tsukada, Y., Bando, Y., Tsujimoto, H., Morishita, R., & Kawashimà, Y. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.09.034 · Cited by 115
Carlson, M., Raab, Y., Peterson, C. G. B., et al. (1999) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01223.x · Cited by 115
Stein, J. M., Ries, J., & Barrett, K. E. (1998) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1998.274.1.g203 · Cited by 115
Review: Anti-adhesion molecule therapy for inflammatory bowel disease
Ghosh, S. K., & Panaccione, R. (2010) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x10373176 · Cited by 112
Hebden, BLACKSHAW, Perkins, Wilson, & Spiller, R. E. (2000) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2000.00697.x · Cited by 109
Animal Models of Inflammatory Bowel Disease: An Overview
Hoffmann, J. C., Pawlowski, N. N., Kühl, A. A., Höhne, W., & Zeitz, M. (2002) · Pathobiology · doi:10.1159/000068143 · Cited by 109
Sasaki, Y., Hada, R., Nakajima, H., Fukuda, S., & Munakata, A. (1997) · PubMed · Cited by 107
Macrophage heterogeneity in normal colonic mucosa and in inflammatory bowel disease.
Allison, M. C., Cornwall, S., Poulter, L. W., Dhillon, A. P., & Pounder, R. E. (1988) · Gut · doi:10.1136/gut.29.11.1531 · Cited by 106
Environmental risk factors in inflammatory bowel disease.
Κoutroubakis, I. E., Manousos, O. N., Meuwissen, S. G. M., & Peña, A. S. (1996) · PubMed · Cited by 102
Nakase, H., Okazaki, K., Tabata, Y., Uose, S., Ohana, M., Uchida, K., Matsushima, Y., Kawanami, C., Oshima, C., Ikada, Y., et al. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35256-5 · Cited by 101
Gong, R., Li, C., Zhu, S., Zhang, Y., Du, Y. L., & Jiang, J. (2011) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2011.04.011 · Cited by 100
The transit of dosage forms through the small intestine
Yuen, K.-H. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.04.045 · Cited by 98
Intestinal Metabolism and Transport of 5-Aminosalicylate
Zhou, S. Y., Fleisher, D., Pao, L., Li, C., Winward, B., & Zimmermann, E. M. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15210-5 · Cited by 98
Ehehalt, R., Braun, A., Karner, M., Füllekrug, J., & Stremmel, W. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.05.014 · Cited by 96
Time-controlled oral delivery systems for colon targeting
Gazzaniga, A., Maroni, A., Sangalli, M. E., & Zema, L. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.5.583 · Cited by 95
Antisense Oligonucleotide Blockade of Tumor Necrosis Factor-α in Two Murine Models of Colitis
Myers, K. J., Murthy, S., Flanigan, A., Witchell, D. R., Butler, M., Murray, S., Siwkowski, A. M., Goodfellow, D., Madsen, K. L., & Baker, B. F. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.040329 · Cited by 93
Jubeh, T. T., Nadler-Milbauer, M., Barenholz, Y., & Rubinstein, A. (2006) · Journal of drug targeting · doi:10.1080/10611860600648429 · Cited by 89
Dendritic cells and scavenger macrophages in chronic inflammatory bowel disease.
Seldenrijk, C. A., Drexhage, H. A., Meuwissen, S. G. M., et al. (1989) · Gut · doi:10.1136/gut.30.4.486 · Cited by 89
Amelioration of experimental colitis by a novel nanoselenium–silymarin mixture
Miroliaee, A. E., Esmaily, H., Vaziri-Bami, A., Baeeri, M., Shahverdi, A. R., & Abdollahi, M. R. (2011) · Toxicology Mechanisms and Methods · doi:10.3109/15376516.2010.547887 · Cited by 88
Zuo, L., Huang, Z., Dong, L., Xu, L., Zhu, Y., Zeng, K., Zhang, C., Chen, J., & Zhang, J. (2009) · Gut · doi:10.1136/gut.2009.184556 · Cited by 88
Harel, E., Rubinstein, A., Nissan, A., Khazanov, E., Nadler-Milbauer, M., Barenholz, Y., & Tirosh, B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024202 · Cited by 87
Design of rolipram-loaded nanoparticles: comparison of two preparation methods
Lamprecht, A., Ubrich, N., Yamamoto, H., Schäfer, U., Takeuchi, H., Lehr, C., Maincent, P., & Kawashima, Y. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00230-9 · Cited by 84
Self-citationRubinstein, A., & Tirosh, B. (1994) · Pharmaceutical Research · doi:10.1023/a:1018961204325 · Cited by 79
Alternative Drug Delivery Approaches for the Therapy of Inflammatory Bowel Disease
Meißner, Y., & Lamprecht, A. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21216 · Cited by 78
Lamprecht, A., Yamamoto, H., Takeuchi, H., & Kawashimà, Y. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.01.003 · Cited by 77
Lamprecht, A., Torres, H. R., Schäfer, U., & Lehr, C. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00331-x · Cited by 70
Self-citationMura, C., Nácher, A., Merino, V., Merino‐Sanjuán, M., Cardá, C., Ruiz-Garcı́a, A., Manconi, M., Loy, G., Fadda, A. M., & Dı́ez-Sales, O. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.06.025 · Cited by 69
Colonic transit of different sized tablets in healthy subjects
Adkin, D. A., Davis, S. S., Sparrow, R. A., & Wilding, I. R. (1993) · Journal of Controlled Release · doi:10.1016/0168-3659(93)90040-c · Cited by 69
Dvořàk, A. M., & Dickersin, G. R. (1980) · PubMed · Cited by 68
Nakase, H., Okazaki, K., Tabata, Y., Ozeki, M., Watanabe, N., Ohana, M., Uose, S., Uchida, K., Nishi, T., Mastuura, M., et al. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.59 · Cited by 67
Serum Electrolytes and Colonic Transfer of Water and Electrolytes in Chronic Ulcerative Colitis
Duthie, H. L., Watts, J. M., deDombal, F. T., & Goligher, J. C. (1964) · Gastroenterology · doi:10.1016/s0016-5085(19)34701-8 · Cited by 62
Bacterial enzymes used for colon-specific drug delivery are decreased in active Crohn's disease
Carrette, O., Favier, C., Mizon, C., Neut, C., Cortot, A., Colombel, J., & Mizon, J. (1995) · Digestive Diseases and Sciences · doi:10.1007/bf02220454 · Cited by 53
Rodrı́guez, M., López, J. R. A., Taboada, C., Seijo, B., & Torres, D. (2001) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357011776658 · Cited by 53
Metabolic pathways of the topical glucocorticoid budesonide in man.
Edsbäcker, S., Jönsson, S., Lindberg, C., Ryrfeldt, Å., & Thalén, A. (1983) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08073-0 · Cited by 51
The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease
Naganuma, M., Fujii, T., & Watanabe, M. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0352-z · Cited by 49
Serpe, L., Canaparo, R., Daperno, M., et al. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.01.013 · Cited by 48
New steroids and new salicylates in inflammatory bowel disease: a critical appraisal: Table 1
Campieri, M. (2002) · Gut · doi:10.1136/gut.50.suppl_3.iii43 · Cited by 45
Reinforcing the mucus: a new therapeutic approach for ulcerative colitis?
Gibson, P. R., & Muir, J. G. (2005) · Gut · doi:10.1136/gut.2004.058453 · Cited by 41
Drug carriers for vascular drug delivery
Koren, E., & Torchilin, V. P. (2011) · IUBMB Life · doi:10.1002/iub.496 · Cited by 40
Onishi, H., Oosegi, T., & Machida, Y. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.02.015 · Cited by 40
Wilson, D. S., Dalmasso, G., Wang, L., Sitaraman, S. V., Merlin, D., & Murthy, N. (2010) · Gastroenterology · doi:10.1016/s0016-5085(10)60164-3 · Cited by 39
Saadatzadeh, A., Atyabi, F., Fazeli, M. R., Dinarvand, R., Jamalifar, H., Abdolghaffari, A. H., Mahdaviani, P., Mahbod, M., Baeeri, M., Baghaei, A., et al. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.00966.x · Cited by 35
FK506 Microparticles Mitigate Experimental Colitis with Minor Renal Calcineurin Suppression
Lamprecht, A., Yamamoto, H., Ubrich, N., Takeuchi, H., Maincent, P., & Kawashimà, Y. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-1186-2 · Cited by 33
Philpott, J. R., & Miner, P. B. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.10.1627 · Cited by 30
Dubey, R., Dubey, R., Omrey, P., Vyas, S. P., & Jain, S. (2010) · Journal of drug targeting · doi:10.3109/10611860903572933 · Cited by 29
Crcarevska, M. S., Dodov, M. G., Petruševska, G., Gjorgoski, I., & Goračinova, K. (2009) · Journal of drug targeting · doi:10.3109/10611860903161310 · Cited by 28
Biodegradable Nanoparticles for Targeted Delivery in Treatment of Ulcerative Colitis
Mahajan, N. M., Sakarkar, D. M., Manmode, A. S., Pathak, V., Ingole, R. S., & Dewade, D. R. (2011) · Advanced Science Letters · doi:10.1166/asl.2011.1247 · Cited by 26
Medical and Dietary Management
Eastwood, M. A. (1975) · Clinics in Gastroenterology · doi:10.1016/s0300-5089(21)00099-7 · Cited by 25
Ramshankar, Y. V., Suresh, S., & Devi, K. (2008) · Clinical Research and Regulatory Affairs · doi:10.1080/10601330802600893 · Cited by 18
The effective therapy of cyclosporine A with drug delivery system in experimental colitis
Fukata, N., Uchida, K., Kusuda, T., Koyabu, M., Miyoshi, H., Fukui, T., Matsushita, M., Nishio, A., Tabata, Y., & Okazaki, K. (2010) · Journal of drug targeting · doi:10.3109/1061186x.2010.511224 · Cited by 16
Animal models of inflammatory bowel disease
Murthy, S., & Flanigan, A. (1999) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7775-6_9 · Cited by 9
Cited by
Mu, J., Zhuang, X., Wang, Q., Jiang, H., Deng, Z., Wang, B., Zhang, L., Kakar, S., Jun, Y., Miller, D., et al. (2014) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201300729 · Cited by 725
Nanoparticles for oral delivery: Design, evaluation and state-of-the-art
Date, A. A., Hanes, J., & Ensign, L. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.016 · Cited by 539
Hua, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00524 · Cited by 527
Hua, S., Marks, E., Schneider, J. J., & Keely, S. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.02.018 · Cited by 494
Sosnik, A., das Neves, J., & Sarmento, B. (2014) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2014.07.010 · Cited by 487
Metadata
- Authors
- Collnot, E.-M., Ali, H., & Lehr, C.-M.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2012-07
- Volume
- 161
- Issue
- 2
- Pages
- 235-246
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W1987166489
- Cited by
- 254
- References
- 123
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.